Goldline Pharmaceutical IPO
Upcoming SMEAlready have an account? Apply now
Goldline Pharmaceutical IPO details
Schedule of Goldline Pharmaceutical
| Issue open date | 12 May 2026 |
| Issue close date | 14 May 2026 |
| UPI mandate deadline | 14 May 2026 (5 PM) |
| Allotment finalization | 15 May 2026 |
| Refund initiation | 18 May 2026 |
| Share credit | 18 May 2026 |
| Listing date | 19 May 2026 |
| Mandate end date | 29 May 2026 |
| Lock-in end date for anchor investors (50%) | 13 Jun 2026 |
| Lock-in end date for anchor investors (remaining) | 12 Aug 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Goldline Pharmaceutical
Goldline Pharmaceutical Limited is a pharmaceutical marketing and distribution company that sells products under the “Goldline” brand in India. The company operates through five product categories: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife and Goldline Wellness, which cater to therapeutic areas such as cardiology, diabetology, orthopaedics, paediatrics, critical care and supportive cancer care. The company does not manufacture products in-house and instead follows a third-party manufacturing model through contract manufacturers that comply with regulatory and quality standards. Its revenue is primarily generated from the sale and distribution of pharmaceutical products and related material supply and procurement support services. Goldline focuses on expanding its product portfolio and market reach through marketing and distribution activities while leveraging external manufacturers for production and formulation support.
Financials of Goldline Pharmaceutical
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 11.61 |
| Fresh Issue – Proceeds go to the company | 11.61 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| Prepayment or repayment of certain outstanding borrowings | 8.35 (71.92%) |
| General corporate purposes | 3.26 (28.08%) |
Strengths
- The company offers pharmaceutical products across five different business segments and therapies.
- Goldline Pharmaceutical has a wide product portfolio catering to physicians, cardiologists, paediatricians, and critical care specialists.
- The company follows an asset-light business model by outsourcing manufacturing to third-party manufacturers.
- The company works with multiple contract manufacturers to support product manufacturing and supply.
- The company focuses on marketing and distribution, helping expand its reach in the pharmaceutical market.
Risks
- The company is fully dependent on third-party manufacturers for the production of its products.
- Any delay or quality issue from contract manufacturers may affect the company’s business operations.
- The company does not have its own research and development facility.
- The company has faced delays in statutory filings and GST payments in the past.
- The business depends heavily on distributors for a significant share of its revenue.